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Abstract
Background: The treatment for deep surgical site infection (SSI) following primary total hip arthroplasty (THA)
varies internationally and it is at present unclear which treatment approaches are used in Australia. The aim of this
study is to identify current treatment approaches in Queensland, Australia, show success rates and quantify the
costs of different treatments.
Methods: Data for patients undergoing primary THA and treatment for infection between January 2006 and
December 2009 in Queensland hospitals were extracted from routinely used hospital databases. Records were
linked with pathology information to confirm positive organisms. Diagnosis and treatment of infection was
determined using ICD-10-AM and ACHI codes, respectively. Treatment costs were estimated based on AR-DRG cost
accounting codes assigned to each patient hospital episode.
Results: A total of n=114 patients with deep surgical site infection were identified. The majority of patients (74%)
were first treated with debridement, antibiotics and implant retention (DAIR), which was successful in eradicating
the infection in 60.3% of patients with an average cost of $13,187. The remaining first treatments were 1-stage
revision, successful in 89.7% with average costs of $27,006, and 2-stage revisions, successful in 92.9% of cases with
average costs of $42,772. Multiple treatments following ‘failed DAIR’ cost on average $29,560, for failed 1-stage
revision were $24,357, for failed 2-stage revision were $70,381 and were $23,805 for excision arthroplasty.
Conclusions: As treatment costs in Australia are high primary prevention is important and the economics of
competing treatment choices should be carefully considered. These currently vary greatly across international settings.
Keywords: Hip replacement arthroplasty, Surgical wound infection, Cost analysis, Outcome assessment, Surgical revision
Background
Surgical site infection (SSI) is a complication caused by
bacterial contamination of the wound during surgery.
SSIs have been reported to occur in 1.5-2.5% of primary
total hip arthroplasty (THA) and estimates vary between
countries [1]. International treatment practices of deep
SSI following THA are also known to differ and strategies
to treating these infections in Australia are not well-
known. As only small single-centre patient outcomes for
a single treatment have been published in this context
[2,3] it remains unclear if other treatment approaches are
commonly utilised. Understanding current practice and
outcomes of deep SSI in Australian hospitals can be useful
for policy makers and allows international comparison.
Quantifying the economic burden of this adverse event
will emphasise the importance of cost-effective infection
control in THA and stimulate research into the cost-
effectiveness of different treatment decisions.
The Center for Disease Control and Prevention (CDC)
distinguishes superficial, deep and joint SSIs [4]. Superfi-
cial SSIs involve the patient’s skin and subcutaneous
tissue and are typically treated with relatively simple
measures, such as antibiotics. Deep SSIs of the deep fascia
& muscle layers and joint SSI on the other hand can have
devastating consequences. Treatment is resource intensive* Correspondence: k.merollini@qut.edu.au1Institute of Health and Biomedical Innovation, Queensland University of
Technology, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia
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and places a high burden on health care systems and pa-
tients’ well-being [5].
The choice of treatment for deep SSI generally de-
pends on a number of factors, including the type of or-
ganism, local factors referring to the bone and tissue
condition, the time of infection onset and the patient’s
general health status [6]. In the case of early infection
onset debridement, antibiotics and implant retention
(DAIR) can be a first management strategy [7]. Revisions
are a treatment alternative to DAIR and can be per-
formed as one- or two-stage procedures. In one-stage re-
visions the prosthesis is exchanged in one operation.
Two-stage revisions on the other hand are more com-
plex and involve: removing the prosthesis; treating the
patient for weeks or months, while they suffer impaired
functional ability and quality of life [8]; inserting a new
prosthesis once the infection is controlled. A last resort
option is to permanently remove the prosthesis in a so-
called Girdlestone procedure (excision arthroplasty) [9].
The literature has shown that 2-stage revisions have
higher success rates but are typically high cost [5,10].
One-stage revisions and DAIR have lower risks but also
have a lower success rate [11].
The objectives of this paper are to describe the frequen-
cies and costs of treatments for deep SSI post primary
THA in Australian hospitals and compare the findings
with practices reported in international jurisdictions.
Methods
Organisation of data
The ‘Queensland Hospital Admitted Patient Data Collec-
tion’ (QHAPDC) database includes administrative and
clinical data for patients admitted to Queensland hospitals
(public/private) [12]. All data were extracted from January
2006 to December 2009 to include diagnosis and treat-
ment codes, gender, admission date, age at admission,
date of procedure performed, separation date, mode of
separation/discharge status, length of stay, major diag-
nostic category and Australian Refined Diagnosis Related
Groups (AR-DRG) cost codes.
Records were linked with pathology records in ‘Auslab’
to confirm the occurrence and type of infection [13].
Auslab pathology data was classed as relevant if it indi-
cated a positive organism isolated in the patient’s hip.
Auslab data was only supplied if a QHAPDC patient
record existed.
Ethics clearance was obtained through the Queensland
University of Technology Research Ethics Unit (Approval
number: 1000000205) and was in compliance with the
Helsinki Declaration on research involving human sub-
jects. Formal data access applications were approved
by data custodians in Queensland Health and Pathology
Queensland.
Patients were selected for analysis if they fulfilled the
following three criteria in chronological order:
1) underwent primary THA (defined by ACHI
treatment codes 49318–00 or 49319–00)
2) presented with deep SSI, i.e. diagnosed with post
procedural wound infection or sepsis following a
procedure (defined by ICD-10-AM diagnosis codes
T81.41 or T81.42)
3) treated with revision surgery (categorised by ACHI
treatment codes) due to deep SSI (defined by Auslab
and criteria shown below).
Criteria used to identify deep/joint SSI
The following criteria were applied to identify deep/joint
infections:
✓ Infection occurs within 1 year of primary THA
(as per CDC definition)
✓ Treatment of infection was ≥2 months after primary
THA (means it is not a superficial SSI as they occur
within 30 days, as per CDC definition)
✓ Only deep infections are treated with:
○ Excisional debridement of soft tissue involving
bone or cartilage
○ Revision/excision arthroplasty
✓ Auslab specimen collection method / specimen site
indicate a deep infection if
○ using an aspirate/ syringe to extract fluid out of hip
○ fluid was collected from the synovial cavity / joint
If the following criteria applied, cases were included as
possibly relevant (could be superficial/deep infections):
✓ Auslab specimen collection method was ‘swab’ or
‘tissue’
✓ Excisional debridement of soft tissue
As Auslab records did not reliably record whether the
infection was deep the criteria outline above were ap-
plied to select deep infections in the data set. Relevant
treatment strategies include debridement, antibiotics &
implant retention (DAIR), 1-stage revision, 2-stage revi-
sion and excision (ACHI treatment codes used for each
category is available from authors on request).
Analysis
The frequencies of different treatment strategies were
estimated over time. Treatment was classed as successful
if no further surgery was undertaken due to deep SSI
within one year post primary THA.
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Costs were derived from treatment codes and related
costs reported in the National Hospital Cost Data Col-
lection [14] for each hospital episode. The average cost
of each treatment pathway was based on the number
of cases in the dataset and average total costs as per
AR-DRG. For patients who underwent primary THA and
SSI treatment in one hospital episode (8%) only costs
exceeding the average costs of a standard primary THA
(AR-DRG code I03C: $18,897) were attributed to the par-
ticular treatment. This is based on the assumption that
costs for primary THA would occur in any case and
hence only infection treatment costs were in addition
to normal costs.
The total average cost of one deep SSI represents the
average treatment costs per patient across all treatment
strategies.
Results
Patient descriptives
Patient characteristics are described in Table 1. There were
10,874 records of patients undergoing primary THA with
n=114 (1.05%) individual patients requiring further hospital
care due to SSI (n=75 definitely deep, n=39 possibly deep).
In this group there were slightly more females (53.5%) and
the majority of patients were aged 60–79 years (65.8%).
Treatment over time
A total of n=114 patients were assessed regarding their
first treatment for deep SSI since primary THA. The ma-
jority of these patients (74%) experienced early infection
onset (≤2 months) which was typically managed with
DAIR. Delayed infections (occurring within 3–12 months)
were most frequently treated with 1-stage revisions (10%),
but also DAIR (8%) and 2-stage revisions (7%). Permanent
removal of the prosthesis (excision) was rarely utilised as
first treatment option.
Treatment outcomes & related costs
The majority of patients (59.6%) underwent DAIR as
first treatment which was successful in eradicating the
infection in 60.3% (n=41) of patients, incurring average
costs of $13,187 (range: $5,565-$36,408). A total of 39.7%
(n=27) of patients first treated with DAIR required mul-
tiple treatments, associated with average total costs of
$29,560 (range: $14,566-$63,069) (see Table 2).
One-stage revision was the initial treatment for 25.4%
(n=26) of patients and resulted in an 89.7% success
rate, costing on average $27,006 (range: $8,957-$36,408).
These costs were based on n=25 patients; 1 patient was
excluded to avoid an overstatement of costs as multiple
treatments were performed within the same hospital
episode (only one cost code was assigned for related
and unrelated treatment). For 10.3% of patients the initial
1-stage revision failed and patients subsequently under-
went DAIR (66.7%) or excision arthroplasty (33.3%). The
average cost of these multiple treatments was $24,357
(range: $15,801-$36,408) (see Table 3).
Two-stage revision was the first treatment in 12.3%
(n=14) of patients and showed a success rate of 92.9%
with average costs of $42,772 (range $15,801-$60,870).
One patient (7.1%) required subsequent treatment was
a 1-stage revision to eradicate the infection, costing
$70,381 for both these procedures (see Table 4).
Excision arthroplasty was the primary treatment in 2.6%
(n=3) of cases, all of which were followed by multiple
Table 1 Characteristics of n=114 patients with deep SSI in
the final dataset
Patient outcomes N %
Total, patients 114 100
Gender
female 61 53.5
male 53 46.5
Age groups
35-49 5 4.4
50-59 20 17.5
60-69 38 33.3
70-79 37 32.5
80-85+ 14 12.3
Classification of infection
Possibly deep infection 39 34.2
Deep/joint infection 75 65.8
Table 2 DAIR treatment failure with subsequent
treatment (n=27)
Treatment
sequence†
N (%) Average
cost (AUD$)
% of
total cost
Total average
cost (AUD$)
2x DAIR 11 (40.7%) 23,026 31.7% 29,560
1x DAIR, 1-stage
Revision
5 (18.5%) 31,769 19.9%
3x DAIR 3 (11.1%) 25,708 9.7%
1x DAIR, 1-stage
Revision, 1x DAIR
2 (7.4%) 63,069 15.8%
1x DAIR, 2-stage
Revision
1 (3.7%) 39,028 4.9%
1x DAIR, Excision 1 (3.7%) 23,973 3.0%
2x DAIR, Excision 1 (3.7%) 23,477 2.9%
3x DAIR, Excision 1 (3.7%) 34,698 4.3%
4x DAIR, Excision,
1x DAIR
1 (3.7%) 47,000 5.9%
8x DAIR 1 (3.7%) 14,566 1.8%
Total 27 (100%) 798,132 100%
†DAIR = Debridement, antibiotics and implant retention.
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DAIR procedures. This treatment pathway resulted in
total average costs of $23,805 (range: $23,477-$24,462)
(see Table 5).
Overall, about one third (32.5%) of deep SSI patients
underwent multiple surgical procedures. The total aver-
age treatment cost per deep SSI was $24,644 across all
treatments or overall $19,688 for patients with DAIR as
1st treatment (success/failure), $26,722 for 1-stage revi-
sion, $44,744 for 2-stage revision and $23,805 for exci-
sion arthroplasty.
An overview of organisms identified in pathology re-
cords is given in Table 6.
Discussion
Australian context
In this study 114 patients required 178 separate surgical
procedures to control the infection. The majority of
these patients had an early onset of deep SSI (74%).
DAIR was most commonly the first choice of treatment
for deep SSI (59.6%) and resulted in the lowest total
average cost of $19,688 when all outcomes and further
treatments were considered. One-stage revision was the
next most frequent first treatment (25.4%) with average
costs of $26,722. Two-stage revisions and excision arthro-
plasty were less commonly chosen as primary treatment
option (12.3% and 2.6%, respectively) and led to costs of
$44,744 and $23,805 respectively. Treatment costs of SSI
following THA in Australia were previously estimated by
Smith et al. [15] based on patient data from the Canberra
Hospital (ACT). The average cost of deep SSI treated with
2-stage revision was $79,623. The cost discrepancy
compared to our estimate may be due to technological
changes, differences in patient co-morbidities or severity of
infection.
Study limitations
We defined deep SSI as per CDC definition as occurring
within one year of primary THA [4] and did not include
late infections. We attempted to select all deep SSI in
the data but 39 indistinguishable cases were included in
the analysis. As these patients may have been treated for
superficial SSI, the proportion of treatment with DAIR
might be inflated and underestimate treatment costs.
The fact that our cost calculations were based on
AR-DRG codes is likely to further understate true costs.
The DRGs reimbursement system has been criticised for
understating costs of treating prosthetic joint infections
and resulting in financial losses for treatment centres
[16,17]. These cost codes estimate only direct in-hospital
costs (ward medical/nursing, non clinical salaries, pa-
thology, imaging, allied, pharmacy, critical care, operating
rooms, emergency department costs, supplies, special
suites, prosthesis, oncost, hotel costs, depreciation and
overhead costs) [14]. For comprehensive cost estimates all
direct post-discharge costs (e.g. antibiotics, primary care
services, travel costs, other pharmaceuticals) and indirect
costs would have to be considered which was not feasible
within this work. Examples of indirect costs would be pro-
duction losses for patients, damage to clinicians’ reputa-
tion and the real economic opportunity cost is the loss
Table 3 One-stage revision treatment failure with
subsequent treatment (n=3)
Treatment
sequence†
N (%) Average
cost (AUD$)
% of
total cost
Total average
cost (AUD$)
1-stage Revision,
Excision
1 (33.3%) 15,801 21.6% 24,357
1-stage Revision,
1x DAIR
1 (33.3%) 20,862 28.6%
1-stage Revision,
3x DAIR
1 (33.3%) 36,408 49.8%
Total 3 (100%) 73,071 100%
†DAIR = Debridement, antibiotics and implant retention.
Table 4 Two-stage revision treatment failure with
subsequent treatment (n=1)
Treatment
sequence
N (%) Average
cost (AUD$)
% of
total cost
Total average
cost (AUD$)
2-stage revision,
1-stage revision
1 (100%) 70,381 100% 70,381
Total 1 (100%) 70,381 100%
Table 5 Excision treatment failure with subsequent
treatment (n=3)
Treatment
sequence†
N (%) Average
cost (AUD$)
% of
total cost
Total average
cost (AUD$)
Excision, 2x DAIR 2 (66.7%) 23,477 65.7% 23,805
Excision, 3x DAIR 1 (33.3%) 24,462 34.3%
Total 3 (100%) 71,416 100%
†DAIR = Debridement, antibiotics and implant retention.
Table 6 Organisms identified in pathology (Auslab)
confirmed infections
Organisms identified (total) N (250) % (100)
Staphylococcus 119 47.6
Coagulase 23 9.2
Enterococccus 23 9.2
Enterobacter 17 6.8
Pseudomonas 17 6.8
Escherichia coli 15 6.0
Candida albicans 8 3.2
Klebsiella 8 3.2
Serratia 8 3.2
Other 11 4.4
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arising from blocked hospital beds or resources due to SSI
treatment that cannot be utilised for other purposes [18].
The overall percentage of deep SSI picked up by our
data was estimated at 1.05%. This might not reflect the
true incidence but is consistent with previous estimates
[19]. Infections as reason for revision may be under-
diagnosed as other conditions caused by infection can be
selected as principal reason for revision, such as loosen-
ing or lysis. Furthermore, our dataset was not designed
to capture follow-up data of patients undergoing pri-
mary THA at the end of our selected time period which
might further underestimate true infection rates.
International comparison
The choice of first treatment varies internationally. A
recent retrospective cohort analysis [20] conducted in
Switzerland recorded the following treatments for 68 pa-
tients with prosthetic joint infection of the hip/knee:
75% had 2-stage revision, 17.6% DAIR, 5.9% 1-stage revi-
sion and 1.5% resection or suppressive antibiotic treat-
ment. This suggests a high cost response to the problem,
that is likely to have good success rates but patients will
have endured the hardship of two stage treatments.
A Taiwanese study [21] of 53 prosthetic joint infection
patients reported the most common treatment strategy
to be DAIR (51%), followed by 2-stage revision (30%)
and resection arthroplasty (19%). It becomes evident that
these settings have a higher proportion of 2-stage revi-
sions rather than 1-stage revisions.
Two-stage revisions used to be the gold standard in
treating deep SSI/prosthetic joint infections and still seem
to be the preferred choice in some countries, including the
United States, Czechoslovakia and Switzerland [1,22,23].
But preferences vary from centre to centre and a general-
isation of treatment patterns is difficult.
rOur study showed that treatment with 2-stage revi-
sion esulted in a higher success rate (92.9%) compared
to 1-stage revision (89.7%) which is in line with findings
from the literature [10,22]. Recent studies from Austria
and New Zealand have argued that the fear of re-infection
should not dominate the choice of treatment and that
1-stage revisions should be favoured as they result in bet-
ter functional outcomes for patients whilst reducing mor-
tality [24,25]. Furthermore, inadequate reimbursement of
in-hospital treatment costs may encourage German faci-
lities to undertake 2-stage revisions rather than 1-stage re-
visions in order to minimise their economic loss [17].
There is a trend towards 1-stage revisions which
should be the preferred treatment as long as no difficult-
to-treat organisms are present (e.g. MRSA). Our data fur-
thermore showed that if the first treatment with DAIR
was unsuccessful repeated DAIR showed good results
when the unclear cases of SSI were included (success rate
of second DAIR was 61%).
The larger challenge
Choosing the right treatment is a complex task and the
costs and health benefits arising from different approaches
should guide surgical decision making. A technically effi-
cient health service should achieve the maximum health
benefits from scarce resources and the costs and benefits
incurred by providers and patients are relevant. Estimating
these is complicated by patient heterogeneity and the dif-
ferent treatment algorithms that have been proposed, con-
sidering various factors, such as the time of infection
onset, type of organism and surgeon experience [6,7].
The priority of orthopaedic surgeons is to achieve
the best clinical outcomes for each individual patient.
In other words, to maximise the quality of life whilst
minimising mortality, often expressed as a single out-
come measure called quality adjusted life years (QALYs).
At the same time, health care facilities face economic
pressures and attempt to minimise treatment costs.
Therefore, they should attempt to provide the best value
for money treatment in terms of health benefits (QALYs
gained). There may be a tension between the needs of
the patient and surgeon and the resources available. This
tension might explain the different treatment patterns
observed in different settings with weaker or stronger
central control of how scarce resources are used.
If only cost outcomes were important DAIR would be
selected as the initial treatment for all patients as it ge-
nerated the lowest average costs (although costs may be
understated due to inclusion of potential superficial SSI
cases). Costs for our cohort of 114 patients would de-
crease by around $5,000/patient, suggesting cost savings
of $570,000. Nevertheless, this simplified calculation dis-
regards underlying factors, such as the presence of re-
sistant organisms or late infection onset which usually
require treatment with 2-stage revision. It also does not
take into account that DAIR is associated with lower
success rates resulting in more patients having to undergo
multiple surgical procedures, each associated with surgical
mortality risks and decreased quality of life.
An adequate evaluation of the cost-effectiveness of dif-
ferent treatment algorithms implies a large amount of
data. Information would be required for each patient
on the total costs of treating them with each alternative
and the expected health benefits in QALYs. A micro-
simulation model might be required that tracks each pa-
tient as an individual, rather than testing alternatives on a
hypothetical cohort of individuals. Due to patient hetero-
geneity, the outcomes of each patient associated with each
treatment alternative would have to be identified to allow
comparisons of cost-effectiveness. Many clinical factors
impacting on the outcomes are not recorded routinely and
are rather based on judgements by experienced surgeons.
A recent decision analysis by Wolf et al. [26] compared
direct exchange and two-stage revision as treatment for
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infected THA in terms of QALYs gained. They found that
direct-exchange arthroplasty resulted in better health out-
comes despite the higher re-infection risk.
Similarly, Fisman et al. [27] published the results of
their decision model for hypothetical patient cohorts to
investigate the management of infected THA using ei-
ther DAIR or 2-stage revision. They found that DAIR
resulted in an increased life expectancy (2.2-2.3 quality-
adjusted life months) and an improved cost-effectiveness
ratio. The authors recommended this treatment for the
US context, given the presence of easy-to-treat organ-
isms and non-loosened prosthesis.
Although these results are useful one should be cau-
tious about drawing conclusions for Australian health
care facilities. Beside differences in health care systems
and likely differences in treatment costs, a major limita-
tion is that treatment patterns differ as our data revealed
that 1-stage revisions are favoured over 2-stage revisions.
Future studies should also consider all relevant treatment
pathways (including multiple treatments) and if possible ac-
count for patient heterogeneity by using a micro-simulation
approach.
To date, no research has addressed the major and
difficult-to-answer question of the ideal treatment for
an individual patient from the health services perspective,
i.e. the treatment with the lowest cost of extra health
gains. The costs of individual treatment pathways identi-
fied in this work might be a first step in providing decision
makers with more information on the cost-effectiveness of
treatment alternatives.
Primary prevention could decrease a large number of SSI
following THA. Relevant infection prevention strategies
should be explored and their cost-effectiveness analysed.
Synthesised information on the effectiveness of strategies as
well as health outcomes is required for a thorough evalu-
ation and would contribute to decreasing the economic
burden of this adverse event following hip arthroplasty.
Conclusions
This paper has contributed to a better understanding of
the treatment and economic consequences of deep SSI
treatment following primary THA in Australia. It is im-
portant to recognise that only accounting for AR-DRG
costs is likely to understate true costs of treating deep
SSI which are still a major burden for patients and health
care facilities.
All efforts should be made to provide patients with the
best possible health outcomes whilst managing infections
in a cost-effective way. Although DAIR has been suggested
in this context for American hospitals, these results may
not be generalisable to the Australian setting and had limi-
tations. A micro-simulation based on individual patients
and a range of clinical factors may be required for reliable
predictions.
The importance of primary prevention should not be
neglected even if the incidence of deep SSI is unlikely to
be zero. The occurrence of SSI might be reduced by intro-
ducing more cost-effective infection prevention measures.
This would also reduce the economic burden of SSI to
healthcare services in the long-term and improve patient
outcomes.
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